Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis
© 2023. Springer Nature Limited..
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, characterized by asthma, eosinophilia and granulomatous or vasculitic involvement of several organs. The diagnosis and management of EGPA are often challenging and require an integrated, multidisciplinary approach. Current practice relies on recommendations and guidelines addressing the management of ANCA-associated vasculitis and not specifically developed for EGPA. Here, we present evidence-based, cross-discipline guidelines for the diagnosis and management of EGPA that reflect the substantial advances that have been made in the past few years in understanding the pathogenesis, clinical subphenotypes and differential diagnosis of the disease, as well as the availability of new treatment options. Developed by a panel of European experts on the basis of literature reviews and, where appropriate, expert opinion, the 16 statements and five overarching principles cover the diagnosis and staging, treatment, outcome and follow-up of EGPA. These recommendations are primarily intended to be used by healthcare professionals, pharmaceutical industries and drug regulatory authorities, to guide clinical practice and decision-making in EGPA. These guidelines are not intended to limit access to medications by healthcare agencies, nor to impose a fixed order on medication use.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Nature reviews. Rheumatology - 19(2023), 6 vom: 09. Juni, Seite 378-393 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Emmi, Giacomo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 29.05.2023 Date Revised 30.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41584-023-00958-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356640183 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356640183 | ||
| 003 | DE-627 | ||
| 005 | 20231226070906.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41584-023-00958-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1188.xml |
| 035 | |a (DE-627)NLM356640183 | ||
| 035 | |a (NLM)37161084 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Emmi, Giacomo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.05.2023 | ||
| 500 | |a Date Revised 30.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. Springer Nature Limited. | ||
| 520 | |a Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, characterized by asthma, eosinophilia and granulomatous or vasculitic involvement of several organs. The diagnosis and management of EGPA are often challenging and require an integrated, multidisciplinary approach. Current practice relies on recommendations and guidelines addressing the management of ANCA-associated vasculitis and not specifically developed for EGPA. Here, we present evidence-based, cross-discipline guidelines for the diagnosis and management of EGPA that reflect the substantial advances that have been made in the past few years in understanding the pathogenesis, clinical subphenotypes and differential diagnosis of the disease, as well as the availability of new treatment options. Developed by a panel of European experts on the basis of literature reviews and, where appropriate, expert opinion, the 16 statements and five overarching principles cover the diagnosis and staging, treatment, outcome and follow-up of EGPA. These recommendations are primarily intended to be used by healthcare professionals, pharmaceutical industries and drug regulatory authorities, to guide clinical practice and decision-making in EGPA. These guidelines are not intended to limit access to medications by healthcare agencies, nor to impose a fixed order on medication use | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antibodies, Antineutrophil Cytoplasmic |2 NLM | |
| 700 | 1 | |a Bettiol, Alessandra |e verfasserin |4 aut | |
| 700 | 1 | |a Gelain, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Bajema, Ingeborg M |e verfasserin |4 aut | |
| 700 | 1 | |a Berti, Alvise |e verfasserin |4 aut | |
| 700 | 1 | |a Burns, Stella |e verfasserin |4 aut | |
| 700 | 1 | |a Cid, Maria C |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen Tervaert, Jan W |e verfasserin |4 aut | |
| 700 | 1 | |a Cottin, Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Durante, Eugenia |e verfasserin |4 aut | |
| 700 | 1 | |a Holle, Julia U |e verfasserin |4 aut | |
| 700 | 1 | |a Mahr, Alfred D |e verfasserin |4 aut | |
| 700 | 1 | |a Del Pero, Marcos Martinez |e verfasserin |4 aut | |
| 700 | 1 | |a Marvisi, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Mills, John |e verfasserin |4 aut | |
| 700 | 1 | |a Moiseev, Sergey |e verfasserin |4 aut | |
| 700 | 1 | |a Moosig, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Mukhtyar, Chetan |e verfasserin |4 aut | |
| 700 | 1 | |a Neumann, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Olivotto, Iacopo |e verfasserin |4 aut | |
| 700 | 1 | |a Salvarani, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Seeliger, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Sinico, Renato A |e verfasserin |4 aut | |
| 700 | 1 | |a Taillé, Camille |e verfasserin |4 aut | |
| 700 | 1 | |a Terrier, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Venhoff, Nils |e verfasserin |4 aut | |
| 700 | 1 | |a Bertsias, George |e verfasserin |4 aut | |
| 700 | 1 | |a Guillevin, Loïc |e verfasserin |4 aut | |
| 700 | 1 | |a Jayne, David R W |e verfasserin |4 aut | |
| 700 | 1 | |a Vaglio, Augusto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nature reviews. Rheumatology |d 2009 |g 19(2023), 6 vom: 09. Juni, Seite 378-393 |w (DE-627)NLM187559821 |x 1759-4804 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:6 |g day:09 |g month:06 |g pages:378-393 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41584-023-00958-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 6 |b 09 |c 06 |h 378-393 | ||